Urologix Announces Signing of an Exclusive Worldwide License for the Prostiva RF Therapy System for BPH

Urologix, Inc. ULGX announces the signing of an Exclusive Worldwide License for the Prostiva RF Therapy System from Medtronic, Inc.MDT. Prostiva RF Therapy is a transurethral needle ablation device that is 510k cleared for the treatment of BPH and is most commonly used in the urologist's office. The license agreement is for a 10-year term and includes the rights to manufacture and market the Prostiva product line in consideration for an upfront license fee and ongoing royalties. The combination of Prostiva RF Therapy with Cooled ThermoTherapy will allow Urologix to offer urologists a broad in-office BPH solution set and will expand Urologix' addressable patient population. "After nearly 15 years, office-based thermotherapies have a well-established place in the urologist's BPH treatment armamentarium," stated William J. Utz, MD FACS, Asst. Clinical Professor of Urology, University of Minnesota. "Of the vast number of technologies introduced, only two have stood the test of time—remaining both market leaders and technological gold standards: CTT and Prostiva. It makes sense that these two technologies join forces under one roof offering urologists the clinical benefit of nondrug treatment alternatives to our symptomatic BPH patients."